Stem Cell Therapy for Congenital Heart Disease
Tsilimigras DI, Oikonomou EK, Moris D, Schizas D, Economopoulos KP, Mylonas KS. Stem Cell Therapy for Congenital Heart Disease. Circulation 2017, 136: 2373-2385. PMID: 29229621, DOI: 10.1161/circulationaha.117.029607.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsCongenital heart diseaseCell therapyHeart diseaseClinical trialsGold standard treatment modalityHypoplastic left heart syndromePulmonary artery hypertensionRight ventricle dysfunctionStandard treatment modalityAlternative treatment optionLarge clinical studiesStem cell deliveryQuality of lifeCell-based therapeutic strategiesArtery hypertensionStem cell-based therapeutic strategiesVentricle dysfunctionSurgical palliationVolume overloadHeart syndromeSafety profileCell-seeded graftsCochrane LibraryTreatment optionsTreatment modalitiesPregnancy associated plasma protein-A as a prognostic biomarker of all-cause mortality and cardiovascular events in patients presenting with chest pain: a systematic review
Papanastasiou CA, Kokkinidis DG, Oikonomou EK, Mantziaris VG, Foley TR, Karamitsos TD, Waldo SW, Armstrong EJ. Pregnancy associated plasma protein-A as a prognostic biomarker of all-cause mortality and cardiovascular events in patients presenting with chest pain: a systematic review. Biomarkers 2017, 23: 1-9. PMID: 29144175, DOI: 10.1080/1354750x.2017.1397194.Peer-Reviewed Original ResearchConceptsIschemic chest painChest painCardiovascular eventsAdverse eventsShort-term adverse eventsShort-term risk stratificationAdverse cardiovascular eventsAcute coronary syndromeGroup of patientsIdentification of patientsStandardized clinical studiesElectronic databases MEDLINEFuture adverse eventsPlasma proteinsCause mortalityCoronary syndromeIschemic originRisk stratificationPrognostic valueCochrane LibraryPatient populationClinical studiesInclusion criteriaPrognostic biomarkerPain